Veracity Capital LLC Reduces Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Veracity Capital LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,266 shares of the medical research company’s stock after selling 51 shares during the quarter. Veracity Capital LLC’s holdings in IQVIA were worth $249,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of IQV. Mutual Advisors LLC lifted its stake in IQVIA by 14.8% during the 4th quarter. Mutual Advisors LLC now owns 1,689 shares of the medical research company’s stock valued at $334,000 after acquiring an additional 218 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of IQVIA by 3.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 36,512 shares of the medical research company’s stock worth $7,175,000 after purchasing an additional 1,172 shares during the last quarter. Advisory Alpha LLC lifted its position in IQVIA by 18.2% during the fourth quarter. Advisory Alpha LLC now owns 3,189 shares of the medical research company’s stock valued at $627,000 after purchasing an additional 492 shares during the period. Howard Capital Management Group LLC grew its position in IQVIA by 1.5% during the 4th quarter. Howard Capital Management Group LLC now owns 121,894 shares of the medical research company’s stock worth $23,953,000 after purchasing an additional 1,860 shares during the period. Finally, Clear Harbor Asset Management LLC raised its stake in shares of IQVIA by 57.8% during the 4th quarter. Clear Harbor Asset Management LLC now owns 6,262 shares of the medical research company’s stock valued at $1,231,000 after buying an additional 2,293 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on IQV. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Evercore ISI lowered their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Barclays cut their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Trading Down 0.7 %

Shares of IQV opened at $204.54 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market cap of $37.12 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The firm’s fifty day moving average is $199.47 and its two-hundred day moving average is $221.09. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.